GT Biopharma, Inc. (GTBP) Ownership
GTBP ownership summary
as of October 17, 2026- Institutions
- 8.4% of shares outstanding
- Insiders
- 10.35% of shares outstanding
- Shares outstanding
- 2.1M
- Float
- 1.7M shares available to trade
- Short interest
- 14.39% 259K shares short
- Days to cover
- 2.24 short interest up 1.1% vs prior month
- Institutions 8.37%
- Insiders 10.35%
- Other investors 81.28%
GTBP top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management, LLC | 0.83% | 376K | $2.6M | −75,476 (−16.7%) | June 30, 2026 |
| 2 | Geode Capital Management, LLC | 0.59% | 267K | $1.9M | −27,671 (−9.4%) | June 30, 2026 |
| 3 | Vanguard Fiduciary Trust Co | 0.50% | 226K | $1.6M | — | June 30, 2026 |
| 4 | HRT FINANCIAL LLC | 0.24% | 107K | $753,194 | +107,140 (0.0%) | June 30, 2026 |
| 5 | Everhart Financial Group, Inc. | 0.22% | 100K | $703,000 | +100,000 (0.0%) | June 30, 2026 |
| 6 | SRS Capital Advisors Inc | 0.21% | 94K | $658,198 | — | June 30, 2026 |
| 7 | Opal Wealth Advisors, LLC | 0.18% | 82K | $575,131 | +81,811 (0.0%) | June 30, 2026 |
| 8 | Northern Trust Corp | 0.17% | 75K | $530,491 | +75,461 (0.0%) | June 30, 2026 |
| 9 | Alongside LLC | 0.14% | 64K | $449,920 | +64,000 (0.0%) | June 30, 2026 |
| 10 | Cetera Investment Advisers | 0.12% | 56K | $393,230 | +55,936 (0.0%) | June 30, 2026 |
| 11 | Seacrest Wealth Management, LLC | 0.11% | 50K | $352,203 | +100 (+0.2%) | June 30, 2026 |
| 12 | KITCHING PARTNERS LLC | 0.11% | 50K | $351,500 | +50,000 (0.0%) | June 30, 2026 |
| 13 | PNC Financial Services Group Inc | 0.09% | 40K | $281,200 | +40,000 (0.0%) | June 30, 2026 |
| 14 | Advisor Group Holdings, Inc. | 0.09% | 38K | $270,655 | +17,500 (+83.3%) | June 30, 2026 |
| 15 | LPL Financial Corp | 0.08% | 36K | $255,744 | +5,997 (+19.7%) | June 30, 2026 |
| 16 | StoneX Group Inc | 0.05% | 23K | $163,504 | +8,502 (+57.6%) | June 30, 2026 |
| 17 | Morgan Stanley - Brokerage Accounts | 0.05% | 23K | $158,688 | +5,974 (+36.0%) | June 30, 2026 |
| 18 | BlueCreek Investment Partners, LLC | 0.05% | 21K | $145,999 | — | June 30, 2026 |
| 19 | CI Private Wealth LLC | 0.04% | 20K | $140,600 | +20,000 (0.0%) | June 30, 2026 |
| 20 | SAGESPRING WEALTH PARTNERS, LLC | 0.04% | 20K | $140,600 | +20,000 (0.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 652K shares and 2 cut 103K.
GTBP top mutual fund and ETF holders
5 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Extended Market Index | 0.37% | 167K | $1.2M | −898 (−0.5%) | August 31, 2026 |
| 2 | Abante Quant Value FI | 0.33% | 148K | $1.0M | +148,057 (0.0%) | August 31, 2026 |
| 3 | Fidelity Series Total Market Index | 0.14% | 62K | $435,431 | — | August 31, 2026 |
| 4 | Fidelity Total Market Index | <0.01% | 2,196 | $15,438 | — | August 31, 2026 |
| 5 | Guggenheim Active Allocation Fund | 0.00% | 6 | $42 | +3 (+100.0%) | May 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
GTBP insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2023-04-11 | Michael Martin Breen | Buy | $15.00 | 1,666 | $24,990 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
GTBP shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns GTBP
Institutional investors own 8.4% of GT Biopharma's shares and insiders 10.35%. The largest holder is Vanguard Capital Management, LLC with 0.83% of the shares (376K), as of June 30, 2026. Among the top 20 institutions, 15 added shares and 2 reduced their stake in the latest filings. Short interest is 14.39% of the float, or 2.24 days of average trading volume. The share count rose 55,025.0% since 2013.
Related: GTBP analyst forecast, GTBP key metrics. See the GTBP stock overview for the latest quote and news.
GTBP ownership FAQ
Who owns the most GT Biopharma stock?
The largest shareholders of GT Biopharma are Vanguard Capital Management, LLC (0.83%), Geode Capital Management, LLC (0.59%), Vanguard Fiduciary Trust Co (0.50%), HRT FINANCIAL LLC (0.24%), Everhart Financial Group, Inc. (0.22%).
What percentage of GT Biopharma is owned by institutions?
Institutions hold 8.4% of GT Biopharma's shares outstanding; insiders hold 10.35%.
Which funds own GT Biopharma?
The largest fund holders of GT Biopharma are Fidelity Extended Market Index (0.37%), Abante Quant Value FI (0.33%), Fidelity Series Total Market Index (0.14%), Fidelity Total Market Index (<0.01%), Guggenheim Active Allocation Fund (0.00%).
What is GT Biopharma's short interest?
259K shares of GT Biopharma were sold short, 14.39% of the float; at the average daily volume it would take 2.24 days to cover.
Are insiders buying or selling GT Biopharma?
Of the latest 1 reported insider transactions in GT Biopharma (since April 11, 2023), 1 were purchases and 0 were sales.
How many shares of GT Biopharma are outstanding?
GT Biopharma has 2.1M shares outstanding, of which 1.7M are in the public float.